Materialise (MTLS) Aktievy
Materialise NV tillhandahåller verktyg för additiv tillverkning och medicinsk programvara samt 3D-printingtjänster i Nord- och Sydamerika, Europa, Afrika och Asien-Stillahavsområdet. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 3/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för MTLS från våra riskkontroller.
MTLS Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Materialise NV Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$6.55 |
| 52 veckors högsta | US$7.50 |
| 52 veckors lägsta | US$4.78 |
| Beta | 1.32 |
| 1 månads förändring | -1.50% |
| 3 månaders förändring | 25.72% |
| 1 års förändring | 23.00% |
| 3 års förändring | -17.61% |
| 5 års förändring | -69.91% |
| Förändring sedan börsintroduktionen | -44.96% |
Senaste nyheter och uppdateringar
Seeking Alpha • Jul 22
Materialise: Maturing Transition Should Lead To Stronger Performance Going Forward
Summary While Materialise's Q1 results were soft, its Medical segment appears to be stabilizing and the software business model transition is nearing completion. Cost discipline and a return to growth should see margins start to consistently move higher, assuming that the macro environment remains stable. Despite the stock moving higher in recent months, a material improvement in performance still isn't priced into the stock. Read the full article on Seeking Alpha
Ny berättelse • Jun 01
Medical And Software Expansion Will Drive Stronger Margins And Earnings Durability
Catalysts About Materialise Materialise provides 3D printing software and services, with a particular focus on medical applications and industrial manufacturing. What are the underlying business or industry changes driving this perspective?
Ny berättelse • May 17
Cloud Software And Medical Constraints Will Pressure 3D Printing Adoption Yet Offer Gradual Upside
Catalysts About Materialise Materialise provides software and manufacturing solutions for 3D printing, with a particular focus on medical applications, industrial production and related services. What are the underlying business or industry changes driving this perspective?Recent updates
Seeking Alpha • Jul 22
Materialise: Maturing Transition Should Lead To Stronger Performance Going Forward
Summary While Materialise's Q1 results were soft, its Medical segment appears to be stabilizing and the software business model transition is nearing completion. Cost discipline and a return to growth should see margins start to consistently move higher, assuming that the macro environment remains stable. Despite the stock moving higher in recent months, a material improvement in performance still isn't priced into the stock. Read the full article on Seeking AlphaNy berättelse • Jun 01
Medical And Software Expansion Will Drive Stronger Margins And Earnings Durability
Catalysts About Materialise Materialise provides 3D printing software and services, with a particular focus on medical applications and industrial manufacturing. What are the underlying business or industry changes driving this perspective?Ny berättelse • May 17
Cloud Software And Medical Constraints Will Pressure 3D Printing Adoption Yet Offer Gradual Upside
Catalysts About Materialise Materialise provides software and manufacturing solutions for 3D printing, with a particular focus on medical applications, industrial production and related services. What are the underlying business or industry changes driving this perspective?Analysartikel • Nov 05
Materialise's (NASDAQ:MTLS) Sluggish Earnings Might Be Just The Beginning Of Its Problems
The market rallied behind Materialise NV's ( NASDAQ:MTLS ) stock, leading do a rise in the share price after its recent...Analysartikel • Oct 06
Materialise NV's (NASDAQ:MTLS) P/E Is On The Mark
With a price-to-earnings (or "P/E") ratio of 54.9x Materialise NV ( NASDAQ:MTLS ) may be sending very bearish signals...Analysartikel • Jul 27
Analyst Estimates: Here's What Brokers Think Of Materialise NV (NASDAQ:MTLS) After Its Second-Quarter Report
Shareholders might have noticed that Materialise NV ( NASDAQ:MTLS ) filed its quarterly result this time last week. The...Analysartikel • Jul 25
Materialise (NASDAQ:MTLS) Is Looking To Continue Growing Its Returns On Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysartikel • May 04
After Leaping 28% Materialise NV (NASDAQ:MTLS) Shares Are Not Flying Under The Radar
Those holding Materialise NV ( NASDAQ:MTLS ) shares would be relieved that the share price has rebounded 28% in the...Seeking Alpha • Feb 24
Materialise: Manufacturing Headwinds Are A Distraction
Summary Materialise's share price dropped significantly after the company reported poor Q4 earnings, which were driven by European automotive market weakness. Despite recent challenges, Materialise's Medical segment continues to perform well and the transition of the Software segment to a subscription model is progressing. The Medical and Software segments are Materialise's primary value drivers and more than justify the company's current valuation. Issues with the Manufacturing segment may need to be resolved before the stock moves higher though. Read the full article on Seeking AlphaAnalysartikel • Feb 13
Materialise NV's (NASDAQ:MTLS) P/E Is Still On The Mark Following 26% Share Price Bounce
Materialise NV ( NASDAQ:MTLS ) shareholders have had their patience rewarded with a 26% share price jump in the last...
Ny berättelse • Feb 09
Launch Of Mimics Flow And ACTech Expansion Will Advance Personalized Medicine
Focus on personalized medical solutions and enhanced platforms could drive revenue growth and improve operational efficiencies and net margins.Analysartikel • Jan 31
Materialise NV (NASDAQ:MTLS) Shares Could Be 28% Above Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Materialise fair value estimate is US$6.77 Materialise is...Analysartikel • Jan 07
These 4 Measures Indicate That Materialise (NASDAQ:MTLS) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Nov 07
Materialise NV's (NASDAQ:MTLS) 27% Jump Shows Its Popularity With Investors
Materialise NV ( NASDAQ:MTLS ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...Seeking Alpha • Nov 04
Materialise: Strong Q3 Results Despite Ongoing Market Headwinds
Summary Materialise continues to grow on the back of its Medical segment, which is expanding at a rapid pace. Materialise's margins will continue to improve going forward, driven by a combination of revenue mix and economies of scale. The ACTech plant expansion will provide a material tailwind in 2025, although disruptions wrought by its startup are likely to negatively impact fourth quarter revenue. Despite the stock moving higher in recent weeks, Materialise remains deeply undervalued. Read the full article on Seeking AlphaAnalysartikel • Nov 01
Materialise's (NASDAQ:MTLS) Strong Earnings Are Of Good Quality
Materialise NV ( NASDAQ:MTLS ) recently posted some strong earnings, and the market responded positively. We did some...Seeking Alpha • Oct 25
Materialise: Medical Business Unit Is The Hidden Value
Summary Materialise NV is a Belgian additive manufacturing company, showing a 14.18% CAGR in its Medical segment from FY18 to FY23. Despite mixed results in other segments, Materialise maintains profitability with positive FCF and a strong balance sheet, supported by €63 million in net cash. The company's strategic positioning in high-value sectors and steady growth, combined with a net cash position and positive FCF, highlight its upside potential. DCF analysis suggests Materialise is undervalued by 35-40%, justifying a "buy" rating due to its innovative edge and expanding market in healthcare. Read the full article on Seeking AlphaAnalysartikel • Oct 25
Is There Now An Opportunity In Materialise NV (NASDAQ:MTLS)?
While Materialise NV ( NASDAQ:MTLS ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Seeking Alpha • Aug 01
Materialise Stock: Nearing An Inflection Point (Rating Upgrade)
Summary Materialise NV continues to face headwinds from soft prototyping demand and muted 3D printer sales. Despite this, Materialise reported solid Q2 results, with growth improving sharply. Recent acquisitions, new software launches, and expanded manufacturing capacity are expected to drive growth going forward. While Materialise's share price has moved higher recently, the prospect of solid growth and significantly higher margins are not priced into the stock. Read the full article on Seeking AlphaAnalysartikel • Aug 01
The Return Trends At Materialise (NASDAQ:MTLS) Look Promising
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Seeking Alpha • Apr 26
Materialise Q1: Progress Against Headwinds
Summary Materialise NV faces a challenging demand environment and is transitioning to a cloud-based SaaS business model, impacting its financial performance. The software business is progressing slowly, while the medical business continues to perform well. The manufacturing business is struggling, but the startup of the expanded ACTech facility later in the year could change this. Macro headwinds and ongoing investments probably limit near-term upside. Longer term, Materialise appears deeply undervalued. Read the full article on Seeking AlphaAnalysartikel • Apr 19
Materialise's (NASDAQ:MTLS) Strong Earnings Are Of Good Quality
Materialise NV ( NASDAQ:MTLS ) just reported healthy earnings but the stock price didn't move much. Investors are...Seeking Alpha • Feb 26
Materialise: Upside From A Transition To Profitability
Summary The demand environment continues to weigh on Materialise's business, although the Medical segment remains a standout, with strong growth and improving margins. The adoption of robotics in joint replacement surgeries poses a threat to Materialise's medical business, though. Investments in the CO-AM platform and the ACTech facility expansion should begin to pay off in 2024, supporting growth and Materialise's competitive position. Given Materialise's relatively low valuation and the potential for solid growth and improving margins, Materialise's stock should do well over the next 1-2 years. Read the full article on Seeking AlphaAnalysartikel • Feb 23
Does Materialise (NASDAQ:MTLS) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jan 31
Materialise NV: Consolidation And New Developments To Emerge As A Rising Star In The Additive Manufacturing Industry
Summary Materialise NV currently exhibits better growth, margins and fundamentals than its main competitors, positioning itself well in an industry that is estimated to grow at a CAGR of 16% until 2032; The medical business unit (c.a. 38.5% of total revenues in 9M23) continues to achieve double-digit growth, with the appointment of the new CEO to focus strongly on this segment; Both the analysis of multiples and DCF here presented show that the current share valuation is 40-45% below its fundamental value. Read the full article on Seeking AlphaAnalysartikel • Jun 14
Here's Why Materialise (NASDAQ:MTLS) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • May 23
Returns On Capital At Materialise (NASDAQ:MTLS) Paint A Concerning Picture
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...Analysartikel • Mar 14
Health Check: How Prudently Does Materialise (NASDAQ:MTLS) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Nov 22
Materialise (NASDAQ:MTLS) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Aktieägarnas avkastning
| MTLS | US Software | US Marknad | |
|---|---|---|---|
| 7D | 0.2% | -5.7% | -2.0% |
| 1Y | 23.0% | -26.4% | 15.1% |
Avkastning vs industri: MTLS översteg US Software branschen som gav -26.4 % under det senaste året.
Avkastning vs Marknaden: MTLS översteg US marknaden som gav 15.1 % under det senaste året.
Prisvolatilitet
| MTLS volatility | |
|---|---|
| MTLS Average Weekly Movement | 5.3% |
| Software Industry Average Movement | 9.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: MTLS har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: MTLS s veckovolatilitet ( 5% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1990 | 2,556 | Brigitte de Vet-Veithen | www.materialise.com |
Materialise NV tillhandahåller additiv tillverkning och medicinska mjukvaruverktyg samt 3D-printingtjänster i Nord- och Sydamerika, Europa, Afrika och Asien-Stillahavsområdet. Bolaget bedriver verksamhet genom tre segment: Materialise Software, Materialise Medical och Materialise Manufacturing. Segmentet Materialise Software erbjuder egenutvecklad programvara i form av program och plattformar som möjliggör och förbättrar funktionaliteten hos 3D-skrivare och utskriftsverksamheter.
Materialise NV Sammanfattning av grunderna
| MTLS grundläggande statistik | |
|---|---|
| Börsvärde | US$374.61m |
| Vinst(TTM) | US$11.45m |
| Intäkter(TTM) | US$304.18m |
33.3x
P/E-förhållande1.3x
P/S-förhållandeÄr MTLS övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| MTLS resultaträkning (TTM) | |
|---|---|
| Intäkter | €267.53m |
| Kostnad för intäkter | €113.41m |
| Bruttovinst | €154.12m |
| Övriga kostnader | €144.05m |
| Intäkter | €10.07m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
Aug 27, 2026
| Vinst per aktie (EPS) | 0.17 |
| Bruttomarginal | 57.61% |
| Nettovinstmarginal | 3.76% |
| Skuld/egenkapitalförhållande | 21.1% |
Hur har MTLS utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/24 23:13 |
| Aktiekurs vid dagens slut | 2026/07/24 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Materialise NV bevakas av 11 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| John Baliotti | Brean Capital Historical (Janney Montgomery) |
| Robert Burleson | Canaccord Genuity |
| Troy Jensen | Cantor Fitzgerald & Co. |